Nothing Special   »   [go: up one dir, main page]

EA200700055A1 - Препаративные формы пероральных лекарственных форм мемантина с немедленным высвобождением - Google Patents

Препаративные формы пероральных лекарственных форм мемантина с немедленным высвобождением

Info

Publication number
EA200700055A1
EA200700055A1 EA200700055A EA200700055A EA200700055A1 EA 200700055 A1 EA200700055 A1 EA 200700055A1 EA 200700055 A EA200700055 A EA 200700055A EA 200700055 A EA200700055 A EA 200700055A EA 200700055 A1 EA200700055 A1 EA 200700055A1
Authority
EA
Eurasian Patent Office
Prior art keywords
forms
memantine
preparative
formal
oral
Prior art date
Application number
EA200700055A
Other languages
English (en)
Other versions
EA011290B1 (ru
Inventor
Ян Янг
Раджив Джанджикхел
Нираньян Рао
Антонио Периклоу
Ваттанапорн Абрамовитц
Махендра Г. Дедихия
Эрхард Зайллер
Бернхард Хауптмайер
Original Assignee
Мерц Фарма Гмбх Унд Ко. Кгаа
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерц Фарма Гмбх Унд Ко. Кгаа filed Critical Мерц Фарма Гмбх Унд Ко. Кгаа
Publication of EA200700055A1 publication Critical patent/EA200700055A1/ru
Publication of EA011290B1 publication Critical patent/EA011290B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Настоящее изобретение относится к твердой пероральной лекарственной форме с немедленным высвобождением, содержащей 1-аминоциклогексаны, предпочтительно мемантин или нерамексан, и необязательно фармацевтически приемлемое покрытие, где активный ингредиент проявляет пропорциональность дозы и высвобождается со скоростью растворения более приблизительно 80% в пределах первых приблизительно 60 мин после поступления указанной формы в среду применения. Лекарственная форма подвергается прямому прессованию и имеет твердость от приблизительно 3 до приблизительно 40 Kр, показывает среднее Tот приблизительно 2 до приблизительно 8 ч с нагрузкой активного ингредиента от приблизительно 2,5 до приблизительно 150 мг. Препаративная форма позволяет создавать композиции с пропорциональными дозами для приема один или два раза в день, а также поддерживать устойчивый средний диапазон T.
EA200700055A 2004-06-17 2005-06-16 Препаративные формы пероральных лекарственных форм мемантина с немедленным высвобождением EA011290B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58124404P 2004-06-17 2004-06-17
PCT/US2005/021284 WO2006096194A2 (en) 2004-06-17 2005-06-16 Drinkable immediate release tablet made with direct compression of memantine or neramexane

Publications (2)

Publication Number Publication Date
EA200700055A1 true EA200700055A1 (ru) 2007-10-26
EA011290B1 EA011290B1 (ru) 2009-02-27

Family

ID=36953777

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200700055A EA011290B1 (ru) 2004-06-17 2005-06-16 Препаративные формы пероральных лекарственных форм мемантина с немедленным высвобождением

Country Status (11)

Country Link
EP (3) EP2601937A1 (ru)
JP (1) JP5025468B2 (ru)
KR (1) KR20090033410A (ru)
CN (1) CN101389315A (ru)
AU (1) AU2005328701B2 (ru)
BR (1) BRPI0512263A (ru)
CA (1) CA2568445C (ru)
EA (1) EA011290B1 (ru)
ES (1) ES2483126T3 (ru)
IL (1) IL179992A (ru)
WO (1) WO2006096194A2 (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2699209A1 (en) 2007-09-12 2009-03-19 Merz Pharma Gmbh & Co. Kgaa 1-amino-alkylcyclohexane derivatives for the treatment and prevention of hearing loss
ES2446365T3 (es) * 2009-06-29 2014-03-07 Merz Pharma Gmbh & Co. Kgaa Procedimiento de preparación de neramexane
JP5738854B2 (ja) * 2009-06-29 2015-06-24 メルツ・ファルマ・ゲーエムベーハー・ウント・コ・カーゲーアーアー ネラメキサンの製造方法
JP5599878B2 (ja) * 2009-06-29 2014-10-01 メルツ・ファルマ・ゲーエムベーハー・ウント・コ・カーゲーアーアー １−アミノ−１，３，３，５，５−ペンタメチルシクロヘキサンを調製する方法
EP2316434A1 (en) * 2009-10-22 2011-05-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Orally disintegrating tablets of memantine
US20110294890A1 (en) * 2010-05-28 2011-12-01 Merz Pharma Gmbh & Co. Kgaa Neramexane for the treatment or prevention of inner ear disorders
US8980318B2 (en) * 2010-06-24 2015-03-17 Merz Pharma Gmbh & Co. Kgaa Neramexane multiple unit dosage form
WO2012048871A1 (en) 2010-10-12 2012-04-19 Merz Pharma Gmbh & Co. Kgaa Memantine for improving cognitive performance in subjects
BR112013008985A2 (pt) 2010-10-12 2016-07-05 Cerecor Inc composições antitussígenas compreendendo memantina
EP2526925A1 (en) 2011-05-23 2012-11-28 Deva Holding Anonim Sirketi A dose adjustable oral pump spray or aerosol spray containing memantine
CN107334744B (zh) * 2017-07-24 2020-09-04 湖南洞庭药业股份有限公司 盐酸美金刚药物组合物和制法
EP3843702B1 (en) 2019-05-31 2023-07-05 Tecnimede, Sociedade Técnico-Medicinal, SA Immediate release fixed-dose combination of memantine and donepezil
CN114199812A (zh) * 2021-12-28 2022-03-18 南通联亚药业有限公司 一种盐酸美金刚缓释制剂中盐酸美金刚的检测方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES413944A1 (es) 1972-04-20 1976-06-01 Merz & Co Procedimiento para la preparacion de compuestos de adamen- tano trisustituidos en las posiciones 1,3,5.
DE2856393C2 (de) 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
US4346112A (en) * 1981-06-29 1982-08-24 University Patents Inc. Composition and method for treating patients having Parkinson's Disease
JPS6216413A (ja) * 1985-07-12 1987-01-24 Teijin Ltd キチン類誘導体を用いた徐放性医薬品組成物
US5334618A (en) 1991-04-04 1994-08-02 The Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5506231A (en) 1989-03-31 1996-04-09 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
DE58905637D1 (de) 1989-04-14 1993-10-21 Merz & Co Gmbh & Co Verwendung von Adamantan-Derivaten zur Prävention und Behandlung der cerebralen Ischämie.
DE4014672A1 (de) * 1990-05-08 1991-11-14 Werner E G Prof Dr Mueller Verwendung von adamantan-derivaten zur zytoprotektion von nicht-infizierten und virus-infizierten lymphozyten als auch anderen zelltypen
US5455279A (en) 1991-04-19 1995-10-03 The Children's Medical Center Corporation Regimen method of mediating neuronal damage using nitroglycerine
US5614560A (en) 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
ES2134804T3 (es) 1991-04-19 1999-10-16 Childrens Medical Center Uso de un compuesto generador de oxido nitrico para prevenir daño neuronal.
DE4225730C2 (de) * 1992-08-04 2003-04-30 Merz Pharma Gmbh & Co Kgaa Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung
GB9517062D0 (en) * 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
JPH0971523A (ja) * 1995-09-07 1997-03-18 Riyuukakusan:Kk 口腔内で崩壊性の速い錠剤
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
US6071966A (en) 1997-06-30 2000-06-06 Merz + Co. Gmbh & Co. 1-amino-alkylcyclohexane NMDA receptor antagonists
CA2292558C (en) * 1997-06-30 2006-09-19 Merz + Co. Gmbh & Co. 1-amino-alkylcyclohexane nmda receptor antagonists
US6413556B1 (en) 1999-01-08 2002-07-02 Sky High, Llc Aqueous anti-apoptotic compositions
SE9901077D0 (sv) 1999-03-23 1999-03-23 Astra Ab Novel use
US6444702B1 (en) 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
TW593223B (en) * 2000-06-20 2004-06-21 Merz Pharma Gmbh & Co Kgaa 1-amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists
US6828462B2 (en) * 2001-11-07 2004-12-07 Merz Pharma Gmbh & Co. Kgaa Unsaturated 1-amino-alkylcyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists
AU2003210486B2 (en) * 2002-01-16 2007-06-28 Endo Pharmaceuticals Inc. Pharmaceutical composition and method for treating disorders of the central nervous system
TW200306189A (en) 2002-03-21 2003-11-16 Merz Pharma Gmbh & Co Kgaa Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists
FR2841138B1 (fr) * 2002-06-25 2005-02-25 Cll Pharma Composition pharmaceutique solide contenant un principe actif lipophile, son procede de preparation
US20040127541A1 (en) * 2002-07-31 2004-07-01 Janet Codd Bicifadine formulation
BRPI0411451A (pt) * 2003-06-16 2006-07-18 Allergan Inc formas de dosagens orais de memantina
AR046314A1 (es) * 2003-11-05 2005-11-30 Merz Pharma Gmbh & Co Kgaa Composiciones que comprenden ciclohexilaminas y aminoadamantanos
RU2766487C2 (ru) * 2004-01-20 2022-03-15 Новартис Аг Композиция и способ прямого прессования
CA2554959A1 (en) * 2004-01-29 2005-08-11 Neuromolecular, Inc. Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions
GT200600008A (es) * 2005-01-18 2006-08-09 Formulacion de compresion directa y proceso

Also Published As

Publication number Publication date
IL179992A0 (en) 2007-05-15
WO2006096194A2 (en) 2006-09-14
EP2397122A3 (en) 2012-01-25
AU2005328701B2 (en) 2009-08-13
WO2006096194A3 (en) 2007-11-22
CA2568445A1 (en) 2006-09-14
CN101389315A (zh) 2009-03-18
JP5025468B2 (ja) 2012-09-12
BRPI0512263A (pt) 2008-02-26
EP2601937A1 (en) 2013-06-12
ES2483126T3 (es) 2014-08-05
JP2008509089A (ja) 2008-03-27
WO2006096194A8 (en) 2007-01-11
EP2397122A2 (en) 2011-12-21
CA2568445C (en) 2011-05-24
AU2005328701A1 (en) 2006-09-14
EP2397122B1 (en) 2014-05-14
EP1765287A2 (en) 2007-03-28
IL179992A (en) 2012-02-29
EA011290B1 (ru) 2009-02-27
KR20090033410A (ko) 2009-04-02

Similar Documents

Publication Publication Date Title
EA200700049A1 (ru) Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
EA200700055A1 (ru) Препаративные формы пероральных лекарственных форм мемантина с немедленным высвобождением
MXPA04003132A (es) Formas orales de administracion de propiverina o sus sales farmaceuticas aceptables con liberacion prolongada.
MY151468A (en) Controlled release solid preparation
NO20064670L (no) Galeniske formuleringer av organiske forbindelser
BR0313424A (pt) Forma de dosagem e processo para a preparação de uma forma de dosagem
ATE424810T1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
EA200600598A1 (ru) Лекарственные формы замедленного высвобождения
GEP20094627B (en) High drug load tablet
SV2008002612A (es) Forma de dosificacion de liberacion retardada oral altamente biodisponibles de succionado de o-desmetilvanlafaxina ref. am101721salvo
IL179718A0 (en) Pharmaceutical composition containing irbesartan
DK0954314T3 (da) Doseringsformer til bedring af mandlig erektionsdefekt
EA200900491A1 (ru) Применение эстрадиола валерата или 17в-эстрадиола в комбинации с диеногестом для перорального лечения для поддержания и/или повышения полового влечения у особи женского пола
MY151470A (en) Controlled release solid preparation
RU2009120990A (ru) Применение тестостерона и агониста 5-нт1а для лечения сексуальной дисфункции
PL1843754T3 (pl) Nowa kompozycja farmaceutyczna zawierająca cyleksetyl kandesartanu jako lipofilową substancję krystaliczną
HUP0105173A2 (hu) Adagolási módszer és készítmény sürgősségi fogamzásgátlásra
UY25234A1 (es) Formulación de liberación prolongada de venlafaxina
MX2010004556A (es) Formulacion farmaceutica de acido clavulanico.
HUP0204202A2 (hu) Ibuprofent tartalmazó hatóanyag-preparátum, eljárás az előállítására és ezt tartalmazó gyógyszerkészítmények
WO2005065639A3 (en) Novel pharmaceutical compositions
MXPA05008843A (es) Sistema terapeutico que comprende amoxicilina y acido clavulanico.
WO2006053089A3 (en) Methods and formulations for making pharmaceutical compositions containing bupropion
RU2009145804A (ru) Аксомадол для лечения боли от артроза
TR200301553A1 (tr) İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU